What do I do now?
The latest news from GenXRT . . .
Generations Radiotherapy Finalizes Plans to Install New Equipment for Precision Cancer
ALABASTER – Generations Radiotherapy & Oncology, PC, owner of the Shelby Cancer Care Center, announced today that it has finalized arrangements for the installation of a new linear accelerator, the centerpiece of radiotherapy treatment delivery. Swedish company Elekta AB was selected as the supplier of the new Infinity accelerator, which will be built in Elekta's factory in Crawley, England beginning a few weeks from now.
This new equipment will bring numerous advances to the Shelby Cancer Care Center, including the ability to deliver stereotactic radiosurgery (SRS) to certain types of primary and metastatic bran malignancies. This is made possible by the Infinity's high-precision delivery system, which includes a 160-leaf multi-leaf collimator which moves at speeds faster than any other such device available today. The new equipment will come with a host of other enhanced capabilities, including improved respiratory gating for tumors that move when a patient breathes, clearer on-board imaging capabilities, and faster overall treatment delivery.
Homewood-based Capital Program Management will oversee preparations for the new linear accelerator in January 2021, while Elekta is expected to have a crew on-site installing the cutting-edge device in February 2021.
When asked to comment, Dr. Christopher Jahraus, the center's owner and radiation oncologist stated, "We chose to go with this remarkable Elekta linear accelerator, because it complements our outstanding array of treatment planning and management systems, which are also developed by Elekta. This will be the only Elekta linear accelerator in the Birmingham metro, and as such, it is evidence of our commitment to ensuring that our patients have the best care available anywhere. This device is part of a series of upgrades our center has been implementing, and will round-out our suite of radiotherapy options."
Generations Radiotherapy anticipates the new device will be in service by early March 2021, after it is put through rigorous testing, calibration, and quality assurance processes.